NPI: 1639124142 · RONCEVERTE, WV 24970 · Anesthesiology Physician · NPI assigned 05/23/2006
Authorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
| Authorized Official | LALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL) |
| NPI Enumeration Date | 05/23/2006 |
Other providers sharing the same authorized official: LALOR, PAULA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 91,253 | $5.39M |
| 2019 | 66,108 | $4.35M |
| 2020 | 84,353 | $3.98M |
| 2021 | 76,573 | $1.59M |
| 2022 | 41,816 | $951K |
| 2023 | 6,912 | $67K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 14,900 | 12,726 | $2.15M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5,866 | 4,955 | $1.76M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,664 | 11,381 | $1.11M |
| 41899 | Unlisted procedure, dentoalveolar structures | 762 | 634 | $651K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 25,248 | 19,087 | $447K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2,433 | 2,076 | $438K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 5,839 | 4,121 | $401K |
| 80053 | Comprehensive metabolic panel | 19,776 | 15,665 | $397K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 8,314 | 6,486 | $378K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 4,060 | 3,346 | $301K |
| J2704 | Injection, propofol, 10 mg | 4,620 | 3,770 | $299K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,829 | 2,523 | $276K |
| 70450 | Computed tomography, head or brain; without contrast material | 3,548 | 3,158 | $244K |
| 36415 | Collection of venous blood by venipuncture | 20,750 | 15,329 | $232K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2,936 | 2,586 | $226K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7,758 | 6,528 | $216K |
| 96375 | Therapeutic injection; each additional sequential IV push | 7,188 | 5,450 | $205K |
| G0378 | Hospital observation service, per hour | 1,980 | 1,602 | $193K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 9,391 | 7,540 | $189K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 3,136 | 2,399 | $186K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5,469 | 4,686 | $181K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,389 | 3,789 | $180K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3,131 | 2,533 | $178K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 875 | 809 | $163K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 2,638 | 2,158 | $160K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 6,619 | 5,418 | $158K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2,820 | 2,519 | $157K |
| 84484 | 7,053 | 4,637 | $141K | |
| J3490 | Unclassified drugs | 18,947 | 6,740 | $135K |
| 80048 | Basic metabolic panel (calcium, ionized) | 6,898 | 5,310 | $132K |
| 71046 | Radiologic examination, chest; 2 views | 3,992 | 3,534 | $131K |
| 81001 | 7,631 | 6,537 | $119K | |
| 71045 | Radiologic examination, chest; single view | 6,288 | 5,354 | $117K |
| 87040 | 5,151 | 2,487 | $103K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 5,062 | 4,154 | $97K |
| 96376 | 2,375 | 1,477 | $95K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 202 | 192 | $95K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 4,435 | 3,857 | $94K |
| 83690 | 4,559 | 3,793 | $88K | |
| 81003 | 6,011 | 5,267 | $83K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 702 | 592 | $81K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 802 | 732 | $81K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,409 | 1,310 | $79K |
| 83735 | 5,098 | 3,512 | $77K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,180 | 936 | $77K |
| 84443 | Thyroid stimulating hormone (TSH) | 2,726 | 2,383 | $73K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2,406 | 2,145 | $71K |
| 80306 | 2,256 | 1,967 | $71K | |
| 82962 | 4,806 | 2,072 | $71K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 958 | 635 | $68K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 2,914 | 2,355 | $67K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 1,175 | 909 | $67K |
| 72125 | Computed tomography, cervical spine; without contrast material | 889 | 794 | $65K |
| 88342 | 1,110 | 981 | $64K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 408 | 393 | $64K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 674 | 452 | $63K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 215 | 171 | $62K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2,252 | 1,387 | $57K |
| 83605 | 3,117 | 2,397 | $57K | |
| 81025 | 1,318 | 1,083 | $54K | |
| 83880 | 1,442 | 1,177 | $54K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 1,049 | 861 | $53K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1,847 | 1,708 | $53K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1,101 | 993 | $52K |
| J7030 | Infusion, normal saline solution , 1000 cc | 668 | 547 | $48K |
| 88304 | 723 | 610 | $48K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,685 | 1,483 | $46K |
| 84703 | 2,104 | 1,826 | $46K | |
| 87077 | 2,538 | 2,245 | $45K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 89 | 82 | $44K |
| 74018 | 642 | 514 | $43K | |
| 82803 | 1,060 | 790 | $42K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 459 | 380 | $42K |
| 87186 | 2,416 | 2,137 | $41K | |
| 93017 | 171 | 158 | $41K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 1,047 | 791 | $41K |
| 85610 | 2,296 | 1,943 | $40K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4,180 | 3,671 | $38K |
| 87430 | 1,373 | 1,248 | $36K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 129 | 124 | $36K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 392 | 380 | $35K |
| 93971 | 442 | 407 | $35K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 299 | 285 | $35K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 91 | 83 | $34K |
| 71250 | 630 | 597 | $33K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 592 | 534 | $29K |
| 85027 | 2,009 | 1,622 | $29K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 744 | 637 | $28K |
| 85379 | 1,029 | 911 | $27K | |
| 78226 | 148 | 133 | $27K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 1,774 | 1,498 | $27K |
| J1940 | Injection, furosemide, up to 20 mg | 226 | 168 | $26K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 365 | 354 | $26K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 861 | 651 | $25K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 958 | 758 | $24K |
| 72100 | 677 | 620 | $24K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 60 | 57 | $23K |
| 87070 | 740 | 617 | $21K | |
| 73562 | 581 | 536 | $21K | |
| 85730 | 1,583 | 1,360 | $21K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 951 | 534 | $20K |
| 76770 | 285 | 275 | $18K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 147 | 132 | $18K |
| 73610 | 401 | 364 | $18K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 706 | 575 | $17K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 249 | 183 | $17K |
| 36600 | 826 | 668 | $17K | |
| 82550 | 620 | 513 | $16K | |
| 97161 | 632 | 535 | $16K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 238 | 214 | $16K |
| 87807 | 445 | 392 | $16K | |
| 73630 | 420 | 376 | $15K | |
| 73030 | 461 | 412 | $13K | |
| 59025 | Fetal non-stress test | 379 | 268 | $13K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 174 | 163 | $13K |
| 73130 | 327 | 294 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 826 | 730 | $12K |
| 82150 | 329 | 278 | $12K | |
| 47562 | 50 | 27 | $12K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 86 | 82 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 477 | 292 | $12K |
| 73110 | 184 | 171 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 254 | 195 | $11K |
| 86850 | 467 | 387 | $11K | |
| 86900 | 583 | 485 | $11K | |
| 86901 | 585 | 485 | $11K | |
| 76641 | 159 | 155 | $10K | |
| 84153 | 191 | 187 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 1,614 | 1,197 | $9K |
| 80061 | Lipid panel | 428 | 379 | $9K |
| 45384 | 51 | 37 | $9K | |
| 86140 | 786 | 622 | $9K | |
| 94060 | 125 | 123 | $8K | |
| 96367 | 106 | 83 | $7K | |
| 82553 | 205 | 180 | $7K | |
| D2710 | 17 | 17 | $7K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 30 | 25 | $7K |
| 70486 | 99 | 94 | $7K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 333 | 281 | $6K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 330 | 282 | $6K |
| 94729 | 90 | 89 | $5K | |
| 85652 | 142 | 132 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 144 | 130 | $5K |
| 74022 | 182 | 161 | $5K | |
| 94726 | 76 | 75 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 133 | 107 | $5K |
| 82140 | 96 | 65 | $5K | |
| J3370 | Injection, vancomycin hcl, 500 mg | 159 | 96 | $4K |
| 84702 | 80 | 69 | $4K | |
| 76536 | 64 | 63 | $4K | |
| 74019 | 96 | 88 | $4K | |
| 80143 | 315 | 269 | $4K | |
| 80179 | 312 | 268 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | 561 | 417 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | 240 | 172 | $4K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 242 | 165 | $4K |
| 84100 | 248 | 178 | $3K | |
| 72050 | 57 | 53 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 116 | 98 | $3K |
| 93970 | 17 | 15 | $3K | |
| 93976 | 13 | 12 | $3K | |
| 90715 | 82 | 73 | $3K | |
| 87184 | 85 | 75 | $3K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 99 | 62 | $2K |
| 51702 | 45 | 41 | $2K | |
| 12002 | 14 | 12 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 28 | 25 | $2K |
| 87046 | 14 | 12 | $2K | |
| 86308 | 61 | 59 | $2K | |
| 80076 | 67 | 53 | $1K | |
| 72141 | 24 | 24 | $1K | |
| 72072 | 39 | 38 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | 84 | 58 | $1K |
| 82272 | 103 | 80 | $1K | |
| 73502 | 25 | 25 | $1K | |
| 87045 | 14 | 12 | $1K | |
| 80050 | General health panel | 39 | 39 | $1K |
| 72131 | 43 | 40 | $999.38 | |
| 87081 | 19 | 13 | $884.26 | |
| 77065 | Tomosynthesis, mammo | 13 | 13 | $680.11 |
| 82010 | 49 | 43 | $616.70 | |
| 74230 | 15 | 15 | $501.47 | |
| 92611 | 15 | 15 | $500.95 | |
| 92526 | 16 | 16 | $498.10 | |
| 73221 | 12 | 12 | $479.60 | |
| 95806 | 12 | 12 | $468.50 | |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 15 | 15 | $438.39 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 15 | 15 | $438.39 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 15 | 15 | $438.39 |
| 80069 | 15 | 12 | $404.03 | |
| 73080 | 15 | 12 | $352.27 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 15 | 13 | $267.34 |
| 84439 | 15 | 15 | $265.49 | |
| 82565 | 30 | 29 | $232.36 | |
| 84520 | 15 | 14 | $194.31 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 17 | 12 | $143.59 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 29 | 25 | $125.95 |
| 94664 | 50 | 42 | $124.22 | |
| 82607 | 12 | 12 | $111.21 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 14 | 12 | $105.27 |
| 82746 | 12 | 12 | $77.08 | |
| 82077 | 458 | 389 | $72.88 | |
| 87205 | 23 | 14 | $38.40 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 13 | 12 | $28.51 |
| 94760 | 58 | 28 | $19.25 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 12 | 12 | $2.24 |
| J7050 | Infusion, normal saline solution, 250 cc | 13 | 12 | $1.24 |